BECTON, DICKINSON AND COMPANY

(BDX)
  Report
Delayed Nyse  -  04:00 2022-08-05 pm EDT
254.23 USD   +0.68%
08/04BECTON DICKINSON & CO Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q)
AQ
08/04SECTOR UPDATE : Health Care Stocks Mixed Pre-Bell Thursday
MT
08/04Becton, Dickinson and Company Seeks M&A
CI
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

BD Voluntarily Recalling Intraosseous Products

06/22/2022 | 05:03pm EDT

By Stephen Nakrosis


Becton, Dickinson and Co. said Wednesday it was voluntarily recalling certain BD Intraosseous Needle Set Kits, BD Intraosseous Manual Driver Kits and BD Intraosseous Powered Drivers.

The company said there are no replacement products currently, adding it will notify customers when replacement products become available. "BD recommends that customers evaluate their clinical needs and consider obtaining and using an alternative intraosseous product," the company said.

The company said users of certain lots may have difficulty separating the stylet from the intraosseous needle, which could result in functional loss of intraosseous access. Other issues include "needle safety mechanism on the stylet not deploying post placement of the intraosseous needle and removal of the stylet from the needle," and "metal discs intended to connect the needle assembly to the magnet in the powered driver sticking unexpectedly to the magnet, rendering the driver unable to be used," the company said.

"These issues may result in delays in care due to limited or non-functioning intraosseous access or could also lead to needlestick injuries," according to the company.

The company said additional information is available on the recall notification section of BD.com.


Write to Stephen Nakrosis at stephen.nakrosis@wsj.com


(END) Dow Jones Newswires

06-22-22 1702ET

All news about BECTON, DICKINSON AND COMPANY
08/04BECTON DICKINSON & CO Management's Discussion and Analysis of Financial Condition and ..
AQ
08/04SECTOR UPDATE : Health Care Stocks Mixed Pre-Bell Thursday
MT
08/04Becton, Dickinson and Company Seeks M&A
CI
08/04TRANSCRIPT : Becton, Dickinson and Company, Q3 2022 Earnings Call, Aug 04, 2022
CI
08/04Becton Dickinson Raises FY22 Guidance
DJ
08/04Becton, Dickinson Reports Higher Fiscal Q3 Results, Raises Full-Year Outlook
MT
08/04BECTON DICKINSON AND : BD REPORTS THIRD QUARTER FISCAL 2022 FINANCIAL RESULTS - Form 8-K
PU
08/04BECTON DICKINSON : Fiscal Q3 Earnings Snapshot
AQ
08/04GUIDANCE : (BDX) BD (BECTON DICKINSON AND COMPANY) Forecasts Fiscal Year 2022 EPS Range $1..
MT
08/04Earnings Flash (BDX) BD (BECTON DICKINSON AND COMPANY) Reports Q3 Revenue $4.64B
MT
More news
Analyst Recommendations on BECTON, DICKINSON AND COMPANY
More recommendations
Financials (USD)
Sales 2022 18 822 M - -
Net income 2022 1 866 M - -
Net Debt 2022 13 567 M - -
P/E ratio 2022 37,2x
Yield 2022 1,49%
Capitalization 72 505 M 72 505 M -
EV / Sales 2022 4,57x
EV / Sales 2023 4,36x
Nbr of Employees 75 000
Free-Float 77,5%
Chart BECTON, DICKINSON AND COMPANY
Duration : Period :
Becton, Dickinson and Company Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BECTON, DICKINSON AND COMPANY
Short TermMid-TermLong Term
TrendsBullishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 16
Last Close Price 254,23 $
Average target price 274,67 $
Spread / Average Target 8,04%
EPS Revisions
Managers and Directors
Thomas E. Polen Chairman, President & Chief Executive Officer
Christopher J. DelOrefice Chief Financial Officer & Executive Vice President
William R. Sigmund Chief Medical Officer & Executive Vice President
Jerry Flasz Chief Information Officer & EVP-Global Services
Elizabeth McCombs Chief Technology Officer & Executive VP
Sector and Competitors
1st jan.Capi. (M$)
BECTON, DICKINSON AND COMPANY3.44%72 505
ABBOTT LABORATORIES-22.37%191 321
MEDTRONIC PLC-9.83%123 942
HOYA CORPORATION-14.17%39 100
DEXCOM, INC.-33.63%34 975
SARTORIUS STEDIM BIOTECH-22.95%34 798